• Description of Treatment Patterns Used for cHL or sALCL [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants Receiving Various Chemotherapy Regimens [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Received Chemotherapy Regimens as per National Guidelines [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Received Radiotherapy Including Site (Extended/Involved) and Total Dosing [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Received Autologous Stem Cell Transplantation (AutoSCT) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Were Eligible for AutoSCT did not Receive it (Including Reasons) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Received Allogeneic Stem Cell Transplantation (AlloSCT) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Pre-SCT Therapy Regimens [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of First Line Treatment Patterns According to Prognostic Group [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Relapse/Refractory (RR) Treatment Patterns [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]

• Description of Treatment Patterns Used for cHL or sALCL [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants Receiving Various Chemotherapy Regimens [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Received Chemotherapy Regimens as per National Guidelines [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Received Radiotherapy Including Site (Extended/Involved) and Total Dosing [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Received Autologous Stem Cell Transplantation (AutoSCT) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Were Eligible for AutoSCT did not Receive it (Including Reasons) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants who Received Allogeneic Stem Cell Transplantation (AlloSCT) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Pre-autoSCT Chemotherapy Regimens [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of First Line Treatment Patterns According to Prognostic Group [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Relapse/Recovery (RR) Treatment Patterns [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]

• Overall Survival (OS) [ Time Frame: From the date of cHL or sALCL diagnosis confirmation until the date of death from any cause or till the latest date of participant observed (up to Month 24) ]
  OS is defined as the time passed from the date of cHL or sALCL diagnosis confirmation until the date of death from any cause or till the latest date of participant observed.
• Disease Free Survival-1 (DSF1) [ Time Frame: From date of complete remission after first line of therapy up to relapse or till the latest date of participant observed (up to Month 24) ]
  DFS1 is defined as the time from the date of complete remission after first line of therapy till relapse or till the latest date of participant observed.
• Freedom From Treatment Failure-1 (FFTF1) [ Time Frame: From date of initiation first therapy until any treatment failures such as disease progression, not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till observed (up to Month 24) ]
  FFTF1 is defined as the time passed from date of initiation first therapy until any treatment failures such as disease progression, do not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till the latest date of participant observed.
• Event Free Survival-1 (EFS1) [ Time Frame: From date of initiation first therapy until therapy discontinuation, not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till observed (up to Month 24) ]
  EFS-1 is defined as the time passed from date of initiation first line therapy until any events such as discontinuation of therapy for any reasons, do not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till the latest date of participant observed.
• Percentage of Participants with Complete Remission (CR) Achieved by the end of Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  CR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is defined as complete disappearance of all target lesions and all nodes with long axis less than (<) 10 millimeter (mm).
• Percentage of Participants With Partial Remission (PR) Achieved by the end of Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  PR based on RECIST 1.1 is defined as greater than or equal to (>=) 30 percent (%) decrease in the sum of longest diameters (SLD) of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis <10 mm.
• Percentage of Participants With Overall Response Achieved by the end of Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Overall response based on RECIST 1.1 is defined as the percentage of participants who have a PR or CR to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity. PR is defined as >=30% decrease in the SLD of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis <10 mm.
• Percentage of Participants With Stable Disease (SD) Achieved by the end of Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  SD based on RECIST 1.1 is defined as changes in the SLD of targeted lesions ranging between reduction of <10% to an increase by <20% without the appearance of a new lesion, and irrespective of positron emission tomography (PET) results.
• Percentage of Participants With Progression Disease (PD) While on the Treatment [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  PD based on RECIST 1.1 is defined as >20% increase in the SLD of target lesions. For small lymph nodes measuring <15 mm post therapy, a minimum absolute increase of 5 mm and the long diameter should exceed 15 mm.
• Percentage of Participants With Relapse (Both Early [<12 Months After the end of First Line Treatment] and Late Relapses) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants With Primary Resistance [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Resistant Participants to the Second and Later Treatment Lines [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants in Whom Brentuximab Vedotin was Used [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Treatment Patterns Containing Brentuximab Vedotin in Clinical Practice [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Disease Free Survival (DFS) After the Treatment Line Including Brentuximab Vedotin Based on the Number of Cycles of Brentuximab Vedotin Performed Within this Treatment Line [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  DFS will be assessed after the treatment line including brentuximab vedotin based on the number of cycles of brentuximab vedotin performed within this Treatment Line. DFS is defined as the time from the date of complete remission till relapse or till the latest date of participant observed.
• FFTF Based on the Number of Cycles of Brentuximab Vedotin Performed Within the Treatment Line [ Time Frame: From initiation therapy date until any treatment failures such as disease progression, not achieving complete remission after therapy, relapse, discontinuation of therapy for complication, death from any cause, or till observed (up to Month 24) ]
  FFTF will be assessed based on the number of cycles of brentuximab vedotin performed within this treatment line. FFTF is defined as the time passed from date of initiation therapy until any treatment failures such as disease progression, do not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till the latest date of participant observed.
• EFS Based on the Number of Cycles of Brentuximab Vedotin Performed Within this Treatment Line [ Time Frame: From initiation therapy date until therapy discontinuation, not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till observed (up to Month 24) ]
  EFS will be assessed based on the number cycles of brentuximab vedotin performed within this treatment line. EFS is defined as the time passed from date of initiation therapy until any events such as discontinuation of therapy for any reasons, do not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till the latest date of participant observed.
• Percentage of Participants With CR Achieved to the end of the Given Treatment Regimen Based on the Number of the Cycles of Brentuximab Vedotin Performed Within This Treatment Line [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  CR based on RECIST 1.1 is defined as complete disappearance of all target lesions and all nodes with long axis <10 mm.
• Percentage of Participants With Overall Response Achieved to the end of the Given Treatment Regimen Based on the Number of the Cycles of Brentuximab Vedotin Performed Within This Treatment Line [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Overall response is defined as the percentage of participants who have a partial or complete response to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity. PR is defined as >=30 % decrease in the SLD of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis <10 mm.
• Percentage of Participants With Progressive Disease Developed While on the Treatment Regimen Including Brentuximab Vedotin Achieved Based on the Number of the Cycles of Brentuximab Vedotin Performed Within This Treatment Line [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  PD based on RECIST 1.1 is defined as >20% increase in the SLD of target lesions. For small lymph nodes measuring <15 mm post therapy, a minimum absolute increase of 5 mm and the long diameter should exceed 15 mm.
• Number of Cycles of Brentuximab Vedotin Before and After Stem Cell Transplantation (SCT) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Clinical Variables for cHL and sALCL at the Time of Primary Diagnosis [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Clinical variable will include stage, histological types, immunohistochemistry data (yes/no), ALK-status (negative/positive), prognostic groups, prognostic risk factors (International Prognostic Score (IPS), International Prognostic Index, Age-adjusted International Prognostic Index, International T-cell Lymphoma Project Score, Prognostic Index for peripheral T-cell lymphoma unspecified [PTCL-U] [PIT]), prognostic risk factors, and risk factors for relapse.
• Distribution of Clinical Variables for cHL and sALCL at the Time of Resistance/Relapses [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Clinical variable will include stage, histological types, immunohistochemistry data (yes/no) and ALK-status (negative/positive).
• Percentage of Participants for Whom PET and PET/Computed Tomography (CT) was Used for Primary Disease Diagnostic and Staging [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants for Whom PET and PET/CT Scan was Used for Interim Treatment Response Evaluation [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• OS Based on use of PET/CT Scan for Initial Disease Staging, Interim and Final Response Assessment During Frontline and Second Line Treatment [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  OS is defined as the time passed from the date of initiation of cHL or sALCL treatment until the date of death from any cause or till the latest date of participant observed. OS will be analyzed by Cox regression.
• Timepoint of Performing Interim Response Evaluation With PET/CT Scan (Number of Cycle After Which the Evaluation is Performed, Time From the Start of Last Cycle of Therapy) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Timepoints will include number of cycle after which the evaluation is performed and time from the start of last cycle of therapy.
• Percentage of Participants for Whom PET and PET/CT Scan Were Used to Evaluate Final Treatment Response [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Timepoint of Performing Final Response Evaluation With PET/CT scan (Number of Cycle After Which the Evaluation is Performed, Time From the Start of Last Cycle of Therapy) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Timepoints will include number of cycle after which the evaluation is performed and time from the start of last cycle of therapy.
• Time of Performing PET and PET/CT Scan After SCT [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Imaging Patterns Used for Primary Disease Diagnostic and Staging in Different Regions of Russia [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Imaging Patterns Used for Treatment Response Evaluation [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Imaging Patterns Used for Disease Control of the Participants Being in Remission [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of cHL or sALCL Participants who Used Healthcare Resources: Hospitalizations, Sick Leave Sheet [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Healthcare resources will include hospitalizations and sick leave sheet.
• Number of Hospitalizations [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Number of Days Spent on Hospital Beds [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Number of Sick Leaves [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Number of Days Spent on Sick Leaves [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Disease Free Survival-2 (DSF2) [ Time Frame: From date of complete remission after second line of therapy up to relapse or till the latest date of participant observed (up to Month 24) ]
  DFS2 is defined as the time from the date of complete remission after second line of therapy till relapse or till the latest date of participant observed.
• Freedom From Treatment Failure-2 (FFTF2) [ Time Frame: From date of initiation second therapy until any treatment failures such as disease progression, not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till observed (up to Month 24) ]
  FFTF2 is defined as the time passed from date of initiation second line therapy until any treatment failures such as disease progression, do not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till the latest date of participant observed.
• Event Free Survival-2 (EFS2) [ Time Frame: From date of initiation second therapy until therapy discontinuation, not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till observed (up to Month 24) ]
  EFS-2 is defined as the time passed from date of initiation second line therapy until any events such as discontinuation of therapy for any reasons, do not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till the latest date of participant observed.
• Number of Cycles of Brentuximub Vedotin Administered in Routine Clinical Practice [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]

• Overall Survival (OS) [ Time Frame: From the date of initiation of cHL or sALCL treatment until the date of death from any cause or till the latest date of participant observed (up to Month 24) ]
  OS is defined as the time passed from the date of initiation of cHL or sALCL treatment until the date of death from any cause or till the latest date of participant observed.
• Disease Free Survival (DSF) [ Time Frame: From date of full remission up to relapse or till the latest date of participant observed (up to Month 24) ]
  DSF is defined as the time from the date of full remission till relapse or till the latest date of participant observed.
• Freedom From Treatment Failure (FFTF) [ Time Frame: From initiation therapy date until any treatment failures such as disease progression, not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till observed (up to Month 24) ]
  FFTF is defined as the time passed from date of initiation therapy until any treatment failures such as disease progression, do not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till the latest date of participant observed.
• Event Free Survival (EFS) [ Time Frame: From initiation therapy date until therapy discontinuation, not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till observed (up to Month 24) ]
  EFS is defined as the time passed from date of initiation therapy until any events such as discontinuation of therapy for any reasons, do not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till the latest date of participant observed.
• Percentage of Participants with Complete Remission (CR) Achieved by the end of Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  CR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is defined as complete disappearance of all target lesions and all nodes with long axis less than (<) 10 millimeter (mm).
• Percentage of Participants With Partial Remission (PR) Achieved by the end of Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  PR based on RECIST 1.1 is defined as greater than or equal to (>=) 30 percent (%) decrease in the sum of longest diameters (SLD) of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis <10 mm.
• Percentage of Participants With Overall Response Achieved by the end of Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Overall response based on RECIST 1.1 is defined as the percentage of participants who have a PR or CR to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity. PR is defined as >=30% decrease in the SLD of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis <10 mm.
• Percentage of Participants With Stable Disease (SD) Achieved by the end of Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  SD based on RECIST 1.1 is defined as changes in the SLD of targeted lesions ranging between reduction of <10% to an increase by <20% without the appearance of a new lesion, and irrespective of positron emission tomography (PET) results.
• Percentage of Participants With Progression Disease (PD) While on the Treatment [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  PD based on RECIST 1.1 is defined as >20% increase in the SLD of target lesions. For small lymph nodes measuring <15 mm post therapy, a minimum absolute increase of 5 mm and the long diameter should exceed 15 mm.
• Percentage of Participants With Relapse (Both Early [<12 Months After the end of First Line Treatment] and Late Relapses) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants With Primary Resistance [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Resistant Participant After two and More Treatment Lines [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants in Whom Brentuximab Vedotin was Used [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Treatment Patterns Containing Brentuximab Vedotin in Clinical Practice [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Regression of Disease free survival (DFS) After the Treatment Line Including Brentuximab Vedotin on the Number of Courses of Brentuximab Vedotin Performed Within the Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  DFS will be assessed after the treatment line including brentuximab vedotin on the number of courses of brentuximab vedotin performed within the Treatment Regimen. DFS is defined as the time from the date of full remission till relapse or till the latest date of participant observed.
• Regression of FFTF on the Number Courses of Brentuximab Vedotin Performed [ Time Frame: From initiation therapy date until any treatment failures such as disease progression, not achieving complete remission after therapy, relapse, discontinuation of therapy for complication, death from any cause, or till observed (up to Month 24) ]
  FFTF will be assessed on the number courses of brentuximab vedotin performed. FFTF is defined as the time passed from date of initiation therapy until any treatment failures such as disease progression, do not achieving complete remission after therapy, relapse, discontinuation of therapy for complications, death from any cause or till the latest date of participant observed.
• Regression of EFS on the Number Courses of Brentuximab Vedotin Performed [ Time Frame: From initiation therapy date until therapy discontinuation, not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till observed (up to Month 24) ]
  EFS will be assessed on the number courses of brentuximab vedotin performed. EFS is defined as the time passed from date of initiation therapy until any events such as discontinuation of therapy for any reasons, do not achieving complete remission after therapy, progression, relapse, death from any cause, late therapy complications including second malignancies or till the latest date of participant observed.
• Regression of Percentage of Participants With CR Achieved to the end of the Given Treatment Regimen on the Number of the Courses of Brentuximab Vedotin Performed Within This Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  CR based on RECIST 1.1 is defined as complete disappearance of all target lesions and all nodes with long axis <10 mm.
• Regression of Percentage of Participants With Overall Response Achieved to the end of the Given Treatment Regimen on the Number of the Courses of Brentuximab Vedotin Performed Within This Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Overall response is defined as the percentage of participants who have a partial or complete response to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity. PR is defined as >=30 % decrease in the SLD of target lesions but not a CR. CR is defined as complete disappearance of all target lesions and all nodes with long axis <10 mm.
• Regression of Percentage of Participants With Progressive Disease Developed While on the Treatment Regimen Including Brentuximab Vedotin Achieved on the Number of Courses of Brentuximab Vedotin Preformed Within This Treatment Regimen [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  PD based on RECIST 1.1 is defined as >20% increase in the SLD of target lesions. For small lymph nodes measuring <15 mm post therapy, a minimum absolute increase of 5 mm and the long diameter should exceed 15 mm.
• Number of Cycles of Brentuximab Vedotin Before and After Stem Cell Transplantation (SCT) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Clinical Variables for cHL and sALCL at the Time of Primary Diagnosis and at the Time of Resistance/Relapses [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Clinical variable will include stage disease, prognostic risk factors, and risk factors for relapse.
• Distribution of Clinical Variables for cHL at the Time of Primary Diagnosis and at the Time of Resistance/Relapses [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Clinical variable will include histological types, immunophenotyping data (yes/no), International Prognostic Score (IPS) score.
• Distribution of Clinical Variables for sALCL at the Time of Primary Diagnosis and at the Time of Resistance/Relapses [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Clinical variable will include immunophenotype, anaplastic lymphoma kinase (ALK)-status, prognostic index for T-cell lymphomas (PIT), IPI score and their components.
• Percentage of Participants for Whom PET and PET/Computed Tomography (CT) was Used for Interim Primary Disease Diagnostic and Staging [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of Participants for Whom PET and PET/CT Scan was Used for Interim Treatment Response Evaluation [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Regression of OS on use of PET/CT Scan for initial disease staging, interim response assessment during frontline treatment and completeness of response assessment during frontline treatment [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  OS is defined as the time passed from the date of initiation of cHL or sALCL treatment until the date of death from any cause or till the latest date of participant observed. OS will be analyzed by Cox regression.
• Regression of OS on Correctness of Using PET/CT Scan for Initial Disease Staging, Interim Response Assessment During Frontline Treatment and Completeness of Response Assessment During Frontline Treatment [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  OS is defined as the time passed from the date of initiation of cHL or sALCL treatment until the date of death from any cause or till the latest date of participant observed. OS will be analyzed by Cox regression.
• Time-point of Performing Interim Response Evaluation With PET/CT Scan (Number of Cycle After Which the Evaluation is Performed, Time After the Last Cycle of Chemotherapy) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Time-points will include number of cycle after which the evaluation is performed and time after the last cycle of chemotherapy.
• Percentage of Participants for Whom PET and PET/CT Scan Were Used to Confirm Completeness of Remission [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Time-point of Performing Completeness if Response Evaluation With PET/CT Scan (Time From the Last Cycle of Chemotherapy) [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Time-points will include time after the last cycle of chemotherapy.
• Percentage of Participants for Whom PET and PET/CT Were Used for Disease Control in Participants Being in Remission [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Time of Performing PET and PET/CT Scan After SCT [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Imaging Patterns Used for Primary Disease Diagnostic and Staging in Different Regions of Russia [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Imaging Patterns Used for Treatment Response Evaluation [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Distribution of Imaging Patterns Used for Disease Control of the Participants Being in Remission [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Frequency of Visits for Disease Control Evaluation [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Percentage of cHL or sALCL Participants who Used Healthcare Resources: Hospitalizations, Disability Determination, Sick Leave Sheet [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
  Healthcare resources will include hospitalizations, disability determination and sick leave sheet.
• Number of Hospitalizations [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Number of Days Spent on Hospital Beds [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Number of Sick Leaves [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]
• Number of Days Spent on Sick Leaves [ Time Frame: From frontline treatment for newly diagnosed participants or within 3 years prior to inclusion in the study for RR cHL or RR sALCL participants till end of participant observation in scope of the study (approximately 5 years) ]

This is a non-interventional, prospective and retrospective study of participants with cHL and sALCL. The study will collect information on therapy and outcome of cHL and sALCL in real-life clinical practice.

The study will enroll approximately 2000 participants. Based on the diagnosis of the disease, participants will be assigned to one of the following groups:

• Newly Diagnosed and RR cHL Participants
• Newly Diagnosed and RR sALCL Participants

This multi-center trial will be conducted in Russia. The retrospective data will be collected for the participants with RR cHL or RR sALCL at the time of enrollment and for participants with RR cHL or RR sALCL within 3 years prior to inclusion in the study at Visit 1 (Baseline). The prospective data will be collected for a period of 2 years from Visit 1 (Baseline) to Visit 5 (Month 24, Final Visit), both for newly diagnosed participants with cHL or sALCL and participants with RR cHL or RR sALCL at the time of enrolment, and participants with RR cHL or RR sALCL within 3 years prior to inclusion in the study.

• Hodgkin Disease
• Lymphoma, Large-cell, Anaplastic

• Newly Diagnosed and RR cHL Participants
  Participants diagnosed with RR cHL at the time of enrollment and RR cHL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed cHL, or RR cHL at the time of enrolment, or RR cHL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.
• Newly Diagnosed and RR sALCL Participants
  Participants diagnosed with RR sALCL at the time of enrollment and RR sALCL within 3 years prior to inclusion in the study will be observed retrospectively. Participants with newly diagnosed sALCL, or RR sALCL at the time of enrolment, or RR sALCL within 3 years prior to inclusion in the study will be observed prospectively for a period of 2 years. Data will be collected from 50 investigational sites to collect information on various treatment options, real-world effectiveness, outcomes and safety within the routine clinical setting.

Inclusion Criteria:

1. Male and female participants 18 years or older by the time of enrollment.
2. Histologically confirmed diagnosis of cHL or sALCL.
3. Newly diagnosed participants, or participants with RR cHL or RR sALCL at the time of enrollment, or participants with RR cHL or RR sALCL within 3 years prior to inclusion in the Study.

Exclusion Criteria:

1. Unconfirmed diagnosis of cHL or sALCL.
2. Current, previous (within the last 3 years) or planned (for the next 2 years) participation in interventional clinical trials.

相关推荐

美国治疗医生

治疗医院

• 
  梅奥诊所

  美国最佳医院荣誉榜第1名
• 
  克利夫兰诊所

  美国最佳医院荣誉榜第2名
• 
  约翰霍普金斯医院

  美国最佳医院荣誉榜第3名
• 
  麻省总医院

  美国最佳医院荣誉榜第4名
• 
  密歇根大学医院

  美国最佳医院荣誉榜第5名
• 
  倉敷中央医院

  日本综合排名第1名
• 
  順天堂医院

  日本综合排名第2名
• 
  藤田医科大学医院（原藤田保健大学医院)

  日本综合排名第3名
• 
  北里大学医院

  日本综合排名第4名
• 
  東京医科大学医院

  日本综合排名第5名

新药特效药

• 阿霉素
• 阿霉素
• 卡莫斯汀
• 格利亚德尔
• 比努
• 金钟
• 长春碱
• 尼伏单抗
• 派姆单抗
• 博来霉素

治疗案例

• 罕见的霍奇金淋巴瘤并未阻止Brian Kozera
• Tierra Ryan-患者故事
• 弗兰克·塞里亚尼-病人故事
• 黛安·摩根（Diane Morgan）-患者故事
• 克里斯·里昂（Chris Lyons）-患者故事
• Madi Jones Hodgkin淋巴瘤故事结节性硬化症，1B期
• Lani Skelley霍奇金淋巴瘤故事经典霍奇金，第2阶段
• Danielle Doyle Hodgkin淋巴瘤故事第二阶段
• Logan Agee霍奇金淋巴瘤故事2A期
• Helicon Kuan Hodgkin淋巴瘤故事2A期

前沿医讯

• 表观遗传学：它如何运作以及对癌症研究意味着什么
• FDA批准了针对淋巴瘤患者的第二种CAR T细胞疗法
• 什么是癌症？常见问题解答
• 感染与癌症：您应该知道的
• 基因疗法如何用于治疗癌症？
• CAR T细胞疗法患者的治疗方法
• 检查点抑制剂：研究人员如何扩展这种形式的免疫疗法
• 什么是癌症的单克隆抗体疗法？
• 飓风过后，波多黎各的癌症患者在达纳-法伯（Dana-Farber）寻找护理和社区
• 在三项癌症诊断后，夫妻交换誓言